Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Brandenburg

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Nephrology|May 29, 2009
Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U"M Cozzolino, V Brandenburg
Seminars in Nephrology|December 16, 2014
The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD)D J A Goldsmith, Z A Massy, V Brandenburg
Der Pathologe|November 6, 2010
[Calciphylaxis. A less well-known, clinically relevant disease]J D Strehl, V Brandenburg, C Forster, et al.
Clinical Laboratory|May 26, 2009
Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patientsW J Fassbender, V Brandenburg, S Schmitz, et al.
Deutsche Medizinische Wochenschrift (1946)|August 30, 2007
[Is there a correlation between C-reactive protein and calcification inhibitors with cardiovascular parameters and risk factors in hemodialysis patients?]G Schlieper, V Brandenburg, Z Djuric, et al.
Plos One|March 3, 2020
Impact of epicardial adipose tissue volume upon left ventricular dysfunction in patients with mild-to-moderate aortic stenosis: A post-hoc analysisF Hardt, M Becker, V Brandenburg, et al.
Kidney International|March 8, 2007
Association of serum fetuin-A levels with mortality in dialysis patientsM M H Hermans, V Brandenburg, M Ketteler, et al.
Pharmacological Research|June 6, 2022
Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal diseaseP Rossignol, J Silva-Cardoso, M N Kosiborod, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Nephrology|May 29, 2009
Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U"M Cozzolino, V Brandenburg
Seminars in Nephrology|December 16, 2014
The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD)D J A Goldsmith, Z A Massy, V Brandenburg
Der Pathologe|November 6, 2010
[Calciphylaxis. A less well-known, clinically relevant disease]J D Strehl, V Brandenburg, C Forster, et al.
Clinical Laboratory|May 26, 2009
Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patientsW J Fassbender, V Brandenburg, S Schmitz, et al.
Deutsche Medizinische Wochenschrift (1946)|August 30, 2007
[Is there a correlation between C-reactive protein and calcification inhibitors with cardiovascular parameters and risk factors in hemodialysis patients?]G Schlieper, V Brandenburg, Z Djuric, et al.
Plos One|March 3, 2020
Impact of epicardial adipose tissue volume upon left ventricular dysfunction in patients with mild-to-moderate aortic stenosis: A post-hoc analysisF Hardt, M Becker, V Brandenburg, et al.
Kidney International|March 8, 2007
Association of serum fetuin-A levels with mortality in dialysis patientsM M H Hermans, V Brandenburg, M Ketteler, et al.
Pharmacological Research|June 6, 2022
Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal diseaseP Rossignol, J Silva-Cardoso, M N Kosiborod, et al.
Pageof 1